eujobs.coEU jobs in brussels
Post a JobHeadhunter

MEDICINES FOR EUROPE

Acronym: -

General Information

Identification Code: 48325781850-28
Website: [object Object]
Entity Form: AISBL
Registration Category: Trade and business associations
Registration Date: 6/16/2009
Last Update: 5/13/2024
EP Accredited Number: 4

Mission & Interests

Goals: Medicines for Europe represents the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value added medicines industries. As a leading partner for better healthcare, we aim to increase the health and wellbeing of all Europeans through better access to high quality medicines. Medicines for Europe members’ portfolio cover 80% of therapy areas, and in so doing, safeguards the sustainability of Europe’s healthcare systems for future generations.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
  • Budget
  • Business and industry
  • Climate action
  • Competition
  • Consumers
  • Customs
  • Digital economy and society
  • Economy, finance and the euro
  • Education and training
  • Employment and social affairs
  • Enlargement
  • Environment
  • European neighbourhood policy
  • External relations
  • Humanitarian aid and civil protection
  • Institutional affairs
  • International co-operation and development
  • Public health
  • Research and innovation
  • Single market
  • Taxation
  • Trade
Levels of Interest:
  • european

Activities

Main EU Legislative Proposals: Medicines for Europe plays an important consultative part in European healthcare policy-making and provides key educational role for its members. Medicines for Europe and its members work with European national governments and the EU institutions to develop sustainable solutions for pharmaceutical care and to increase Europe’s competitive strength in the global pharmaceutical medicines market. Medicines for Europe is engaged to work on a variety of EU pharmaceutical policies and legislative proposals, which include, but is not limited to: The implementation of the pharmaceutical and IP strategies; The implementation of the SPC Manufacturing Waiver, which was introduced in July 2019; the broad review of the pharmaceutical incentives (e.g. Bolar, variations, orphan and paediatric medicines, etc.); the review of the SPC legislation (i.e. Unitary SPC, SPC legal review, etc.) and the patent system; the industrial policy to stimulate more investments in Active Pharmaceutical Ingredients’ production in Europe and critical medicines ; the possible review of the Transparency Directive on pharmaceutical; the rules on pharmaceuticals’ public procurement; all competition policies aimed to ensure off-patent medicines timely access to the market; all policies related to shortages of medicines; the policy discussions around pharmaceuticals in the environment; education and policies regarding biosimilar medicines; the development of information and awareness around value added medicines; the EMA work around generic and biosimilar medicines; the work of the Pharmaceutical Committee more generally; trade agenda; digital agenda.
Communication Activities: List of activities • conferences, webinars, communication campaigns and workshops organisation • membership services and publications (EU Members Brief and highlights) • scientific, legal and economic assessment reports • EU and International representation
EU Supported Forums and Platforms: Antimicrobial Resistance One Health Network#E03853#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3853 #MEMBER #C#IndustryMedical Device Coordination Group#X03565#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3565 #OBSERVER #C#Industry10 - International Matters#X03565/11#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=100607 #OBSERVER #C#Industry06 - Borderline and Classification (B&C)#X03565/8#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=100603 #OBSERVER #C#IndustryEXPERT GROUP FOR THE IMPLEMENTATION OF THE EU ANTI-TORTURE REGULATION (ATR) #E03762#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3762 #MEMBER #C#Industry#SMEs
Inter-institutional or Unofficial Groupings: N/A

Head Office

Address: RUE D'ARLON, 50
Post Code: 1000
City: BRUSSELS
Country: BELGIUM
Phone: [object Object]

EU Office

Address: RUE D'ARLON, 50
Post Code: 1000
City: BRUSSELS
Country: BELGIUM
Phone: [object Object]

Financial Data

New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Complementary Information: The grants indicated above are part of a total grant of 208.062 Euro that is spread over a 5 year period. While in the financial year 1/2023-12/2023 there was no grant (considered 'current financial year' above), on 4 February 2024 Medicines for Europe received a grant of 20 505,91 EUR, still part of the same total grant.

Membership Information

Members10 Percent: 0
Members25 Percent: 5
Members50 Percent: 0
Members75 Percent: 1
Members: 8
Members F T E: 4

Structure

Structure Type: Structure
Is Member Of: http://www.medicinesforeurope.com/medicines-for-europe/#section-5
Organisation Members: • Consultative status with World Intellectual Property Organization (WIPO) • Founding Member International Generic and Biosimilar Pharmaceutical Alliance (IGBA) • Member Federation of European and International Associations Established in Belgium (FAIB)